CEO Medical Leave: Zura Bio's CEO, Robert Lisicki, will begin a medical leave starting Friday.
Impact on Company: The announcement may raise concerns about leadership continuity and company operations during his absence.
ZURA
$4.07+Infinity%1D
Analyst Views on ZURA
Wall Street analysts forecast ZURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZURA is 11.67 USD with a low forecast of 2.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
4 Analyst Rating
Wall Street analysts forecast ZURA stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for ZURA is 11.67 USD with a low forecast of 2.00 USD and a high forecast of 18.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
1 Hold
0 Sell
Strong Buy
Current: 4.020
Low
2.00
Averages
11.67
High
18.00
Current: 4.020
Low
2.00
Averages
11.67
High
18.00
Clear Street
NULL
to
Buy
initiated
$18
2025-11-12
Reason
Clear Street
Price Target
$18
2025-11-12
initiated
NULL
to
Buy
Reason
Clear Street initiated coverage of Zura Bio with a Buy rating and $18 price target. The firm said he rating reflects "strong conviction" in tibulizumab's ability to lead in hidradenitis suppurativa and systemic sclerosis. The firm also believes tibulizumab is well positioned to set a new standard.
H.C. Wainwright
H.C. Wainwright
Neutral
downgrade
$3 -> $2
2025-08-19
Reason
H.C. Wainwright
H.C. Wainwright
Price Target
$3 -> $2
2025-08-19
downgrade
Neutral
Reason
H.C. Wainwright lowered the firm's price target on Zura Bio to $2 from $3 and keeps a Neutral rating on the shares. The firm updated the company's model post the Q2 report to reflect increases in potentially dilutive shares outstanding.
Oppenheimer
Oppenheimer
Outperform
downgrade
$17 -> $16
2025-08-15
Reason
Oppenheimer
Oppenheimer
Price Target
$17 -> $16
2025-08-15
downgrade
Outperform
Reason
Oppenheimer lowered the firm's price target on Zura Bio to $16 from $17 and keeps an Outperform rating on the shares after the company reported Q2 financial results and provided an update on their ongoing clinical studies of tibulizumab, with the global Phase 2 TibuSHIELD study in HS having launched in May. The firm's reported Q2 ending cash of $154.5M is anticipated to support operations through 2027 and readouts from both ongoing studies of tibulizumab.
Oppenheimer
Oppenheimer
Outperform
downgrade
$19 -> $17
2025-05-09
Reason
Oppenheimer
Oppenheimer
Price Target
$19 -> $17
2025-05-09
downgrade
Outperform
Reason
Oppenheimer lowered the firm's price target on Zura Bio to $17 from $19 and keeps an Outperform rating on the shares. The firm notes Zura reported Q1 results with tibulizumab continuing to advance. The Phase 2 TibuSURE trial in SSC is active with efforts focused on site contracting and activation. Next up the HS study is slated to begin Q2 2025.
About ZURA
Zura Bio Limited is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies. It is developing a portfolio of therapeutic indications for tibulizumab (ZB-106), crebankitug (ZB-168), and torudokimab (ZB-880) with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases, including systemic sclerosis and other indications with unmet needs. ZB-106 is an immunoglobulin G single-chain variable fragment bispecific dual-antagonist antibody engineered by the fusion of TALTZ and tabalumab that neutralize interleukin-17A (IL-17A) and BAFF. ZB-168 is a fully human, high affinity monoclonal antibody that binds and neutralizes the IL-7 receptor chain alpha chain. ZB-880 is a fully human, high affinity monoclonal antibody that neutralizes IL-33, preventing ST2-dependent and ST2-independent inflammation.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
